FDA approves once-weekly efanesoctocog alfa, a new class of high-sustained factor VIII therapy for haemophilia A: Swedish Orphan Biovitrum AB ...Middle East

STOCKHOLM, Feb. 24, 2023 /PRNewswire/ -- Sobi® today announced that the US Food and Drug Administration (FDA) has approved efanesoctocog alfa [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], a first-in-class, high-sustained factor VIII replacement therapy for adults...

Hence then, the article about fda approves once weekly efanesoctocog alfa a new class of high sustained factor viii therapy for haemophilia a swedish orphan biovitrum ab was published today ( Friday 24/02/2023 - 09:52 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA approves once-weekly efanesoctocog alfa, a new class of high-sustained factor VIII therapy for haemophilia A: Swedish Orphan Biovitrum AB )

Also on site :

• Kanye “Ye” West Reportedly Struggles to Stay Awake While Testifying at Los Angeles Mansion Trial
• Billboard Staff Reacts To & Ranks Harry Styles’ New Album ‘Kiss All the Time. Disco, Occasionally’ .. Billboard News
• Ted Season 2 Chaos: Seth MacFarlane & Cast Talk AI Bill Clinton, Dropping Trou, And Making Out With A Teddy Bear